

Agenda


- Disease background and unmet need
- LAF237 background and New MoA data
- LAF237 review of new phase IIb/III data
 - Study 2309 Phase III monotherapy (52 week) vs. metformin
 - Study 2329 Phase III monotherapy dose comparison
 - Study 1202 Phase IIb monotherapy dose-ranging
 - Study 2311 Phase III add-on to insulin
- Timings and future clinical program

11 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 – Oral DPP4¹ Inhibitor with Potential for Sustainable Diabetes Control

- First in a highly attractive new class of compounds (incretin enhancer)
- Effective as monotherapy and in combination
- Effectively reduces HbA1c
- Good tolerability with no nausea and no significant effect on weight
- Has the potential for disease modification based on islet-cell effects




¹ Dipeptidyl peptidase IV
² Glucagon-like-peptide-1
³ Gastric inhibitory polypeptide

12 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Increases β -Cell Responsiveness to Glucose in T2DM




Adapted from Mari A, et al. J. Clin Endocrinol Metab 90:4888-4894, 2005

13 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Improves and Sustains Islet Cell Function and Insulin Sensitivity over 1 year in T2DM

Patients failing on stable metformin therapy




*P < .05 vs. placebo; †P < .01 vs. placebo

Adapted from Ahren B, et al. Diabetes Care. 2005;28:1936-1940.

14 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



Improvements in Islet Cell Function and Insulin Sensitivity With LAF237 Support Sustained Efficacy Seen Over 1 year



15 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



Agenda


- Disease background and unmet need
- LAF237 background and New MoA data
- **LAF237 review of new phase IIb/III data**
 - Study 2309 Phase III monotherapy (52 week) vs. metformin
 - Study 2329 Phase III monotherapy dose comparison
 - Study 1202 Phase IIb monotherapy dose-ranging
 - Study 2311 Phase III add-on to insulin
- Timings and future clinical program

16 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



Phase III Trial Design for Study 2309 – Long-term LAF237 Monotherapy

Drug naïve patients with T2DM and HbA1c 7.5-11%
Objective - HbA1c reduction at 12 months and maintenance to 2 years




Source: Study 2309 data on file

17 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



52 Week Data with Monotherapy Confirm Early and Sustained Reductions in HbA1c




Source: Study 2309 data on file per protocol population

18 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani

Intent to treat: LAF237 -1.0%
metformin -1.4%



Both LAF237 and Metformin Demonstrate Body Weight Neutrality Unlike SUs¹ and TZDs²



¹ Sulfonylureas ² Thiazolidinediones
Source: Study 2309 data on file

19 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 is Better Tolerated than Metformin


AEs of special interest	LAF237 100 mg (%) (n=526)	metformin 2 000 mg (%) (n=254)
Hypertension	3.7	4.8
Edema	2.5	3.6
Diarrhea	6.0	26.2
Paresthesia	0.8	2.0
Nausea	3.3	10.3
Myalgia	2.3	0.8
Hypoglycemia	0.6	0.4
ECG ¹ abnormalities	11.0	12.0

¹ Electrocardiogram
Source: Study 2309 data on file

20 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Has a Superior GI Tolerability Profile to Metformin



Source: Study 2309 data on file

21 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani




Phase III Trial Design for Study 2329 – LAF237 Dose Comparison

Drug naïve patients with T2DM and HbA1c 9-11%

Primary objective: HbA1c reduction from baseline – LAF237 50 mg and 100 mg total daily dose

Pioglitazone used as a positive control for study validation




Source: Study 2329 data on file

22 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Achieves Excellent, Dose-proportional Reductions in HbA1c

Duration: 12 weeks




Source: Study 2329 data on file

23 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Demonstrates Excellent Responder Rates

Duration: 12 weeks



Source: Study 2329 data on file


24 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



Phase IIb Trial Design for Study 1202- LAF237 Dose-ranging Study

Drug naïve patients with T2DM and HbA1c 7.5-11%

Primary objective: HbA1c reduction from baseline – LAF237 20 mg, 50 and 100 mg vs. placebo




Source: Study 1202 data on file

25 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Demonstrates Excellent, Dose-proportional Reduction in HbA1c

Duration: 12 weeks




Source: Study 1202 data on file *p < 0.001 versus placebo and baseline

26 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Phase III Trial Design for Study 2311 Add-on to Insulin

Patients with T2DM on insulin, HbA_{1c} 7.5–11%
Primary objective: To improve metabolic control as add-on to insulin




Source: Study 2311 data on file

27 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Significantly Reduces HbA_{1c} in T2DM Patients Requiring Insulin

Duration: 24 weeks




Source: Study 2311 data on file

28 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



Reductions of HbA1c Achieved With Less Insulin Requirements and No Severe Hypoglycemic Events

Duration: 24 weeks



¹ Blood glucose < 3.1 and symptoms suggestive of hypoglycemia and patient unable to initiate self treatment

Source: Study 2311 data on file

29 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 New Phase IIb/III Data Summary


New Phase IIb/III data confirms that LAF237

- Reduces HbA1c levels in a dose-proportional, clinically meaningful manner in monotherapy and combination with insulin
- Sustains meaningful HbA1c reductions out to one year
- Has neutral body weight effects associated with HbA1c improvements
- Is very well tolerated
- Is associated with fewer severe hypoglycemic episodes when added to insulin
- Has the ideal profile as 'first drug of choice' for combination treatment due to efficacy and safety profile, lack of drug-drug interactions and complementary mechanism of action

30 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



LAF237 Addresses Multiple Important Defects in T2DM Treatment



Adapted from DeFronzo RA. *Br J Diabetes Vasc Dis.* 2003;3(suppl 1):S24-S40
31 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani




Agenda

- Disease background and unmet need
- LAF237 background and New MoA data
- LAF237 review of new phase IIb/III data
 - Study 2309 Phase III monotherapy (52 week) vs. metformin
 - Study 2329 Phase III monotherapy dose comparison
 - Study 1202 Phase IIb monotherapy dose-ranging
 - Study 2311 Phase III add-on to insulin
- **Timings and future clinical program**

32 London Pharmaceutical Pipeline Event 2005 / Ameet Nathwani



Overview of Timing of Study Starts and Expected Data for LAF237



Summary and Conclusions

- Pancreatic islet dysfunction is the key determinant of the onset and progression of type 2 diabetes
- Clinical data confirms that LAF237 restore insulin sensitivity and normalises islet cell function long-term in patients with T2DM
- New phase IIb/III data shows that LAF237 has the ability to sustain reductions in HbA1c to clinically meaningful levels long-term in monotherapy and combination with insulin
- Further pivotal clinical data will be available in early 2006

An extensive clinical trials program with LAF237 will define the role of islet cell protection in

- Delaying onset of T2DM (prevention)
- Slowing progression and maintaining control in T2DM (durability)
- Reducing CVM complications (disease modification)